Mechanistically, we uncovered a SETD2 loss of function-dependent occurrence of an aberrant ATG12-containing complex, in addition to the conventional ATG5/ATG12 covalent complex, as well as increased of free ATG12, in RCC cells carrying the SETD2 gene mutation. The gene discussed is SETD2; the disease is renal cell carcinoma.